Related references
Note: Only part of the references are listed.Data Sharing, Year 1-Access to Data from Industry-Sponsored Clinical Trials
Brian L. Strom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Dinesh Khanna et al.
ARTHRITIS AND RHEUMATISM (2013)
Survival and Prognostic Factors in Systemic Sclerosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
Guillaume Lefevre et al.
ARTHRITIS AND RHEUMATISM (2013)
Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era
Melvyn Rubenfire et al.
CHEST (2013)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
Zhi-Cheng Jing et al.
CIRCULATION (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Does Raising Type 1 Error Rate Improve Power to Detect Interactions in Linear Regression Models? A Simulation Study
Casey P. Durand
PLOS ONE (2013)
Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials
Masataka Kuwana et al.
BMJ OPEN (2013)
The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH
Philip J. Clements et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Victor E. Tapson et al.
CHEST (2012)
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
Nicole B. Gabler et al.
CIRCULATION (2012)
Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension
Julio Sandoval et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
Pulmonary Hypertension in Systemic Sclerosis
Soumya Chatterjee
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Identifying Systemic Sclerosis as a Unique Phenotype
Lorinda Chung et al.
CHEST (2010)
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza et al.
CIRCULATION (2010)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Marc Humbert et al.
CIRCULATION (2010)
Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease
J. Gerry Coghlan et al.
CURRENT OPINION IN PULMONARY MEDICINE (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Connective Tissue Disease-associated Pulmonary Arterial Hypertension in the Modern Treatment Era
Robin Condliffe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy
M. J. Overbeek et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma
Margaret C. Garin et al.
JOURNAL OF RHEUMATOLOGY (2009)
Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis
Yoland Schoindre et al.
JOURNAL OF RHEUMATOLOGY (2009)
Pulmonary hypertension
Gorev Grubu Uyeleri et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
J. Avouac et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
Reda E. Girgis et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Changes in causes of death in systemic sclerosis, 1972-2002
Virginia D. Steen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases
Peter Dorfmueller et al.
HUMAN PATHOLOGY (2007)
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
C. P. Denton et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension
Micah R. Fisher et al.
ARTHRITIS AND RHEUMATISM (2006)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Last observation carry-forward and last observation analysis
J Carpenter et al.
STATISTICS IN MEDICINE (2004)
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
SM Kawut et al.
CHEST (2003)
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
D Mukerjee et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Sample size slippages in randomised trials: exclusions and the lost and wayward
KF Schulz et al.
LANCET (2002)
Share Paper
